Journal Mobile Options
Table of Contents
Vol. 28, No. 1, 2007
Issue release date: December 2006

Serum Levels of Hepatocyte Growth Factor/Scatter Factor in Patients with Liver Metastases from Breast Cancer

Eichbaum M.H.R. · de Rossi T.M. · Kaul S. · Bruckner T. · Schneeweiss A. · Sohn C.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Objective: Recent studies have shown that the pleiotropic cytokine hepatocyte growth factor/scatter factor (HGF/SF) and its receptor c-Met play major roles in the malignant progression of numerous tumors. For patients with breast cancer liver metastases, increased serum levels of HGF/SF have been reported. We studied the relationship between the clinical course of the disease and the serum levels of HGF/SF in such patients. Methods: We examined 51 patients treated for breast cancer liver metastases. Serum concentrations of HGF/SF were measured before each therapy cycle and compared to the corresponding tumor marker levels. Results: Mean serum levels of HGF/SF in patients with liver metastases were increased above the reported reference levels of primary breast cancer patients. Serum levels of HGF/SF were correlated with tumor marker levels in a logarithmic relation (r = 0.47, p < 0.001). In some cases serum concentrations of HGF/SF changed similarly to the course of the corresponding tumor markers. Conclusions: Serum levels of HGF/SF are associated with the clinical course of metastatic breast cancer patients with liver metastases. Further studies are required to clarify the potential value of the HGF/SF serum concentration as a tumor marker. HGF/SF and its receptor c-Met should be further evaluated as therapeutic targets.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, Tashiro K, Shimizu S: Molecular cloning and expressing of human hepatocyte growth factor. Nature 1989;342:440–443.
  2. Nakamura T, Nawa K, Ichihara A: Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun 1984;122:1450–1459.
  3. Matsumoto K, Nakamura T: Hepatocyte growth factor as a tissue organizer for organogenesis and regeneration. Biochem Biophys Res Commun 1997;239:639–644.
  4. Huh C-G, Factor VM, Sanchez A, Uchida K, Conner EA, Thorgeirsson SS: Hepatocyte growth factor/c-met signalling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci USA 2004;101:4477–4482.
  5. Stoker M, Gherardi E, Perryman M, Gray J: Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 1987;327:239–242.
  6. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;12:915–925.

    External Resources

  7. Naughton M, Picus J, Zhu X, Catalona WJ, Vollmer RT, Humphrey PA: Scatter factor-hepatocyte growth factor elevation in the serum of patients with prostate cancer. J Urol 2001;165:1325–1328.
  8. Han S-U, Lee J-H, Kim W-H, Cho Y-K, Kim M-W: Significant correlation between serum level of hepatocyte growth factor and progression of gastric carcinoma. World J Surg 1999;23:1176–1180.
  9. Hu RH, Lee PH, Yu SC, Sheu JC, Lai MY: Serum hepatocyte growth factor before and after resection for hepatocellular carcinoma. Hepatogastroenterology 1999;46:1842–1847.
  10. Fukuura T, Miki C, Inoue T, Matsumoto K, Suzuki H: Serum hepatocyte growth factor as an index of disease status of patients with colorectal carcinoma. Br J Cancer 1998;78:454–459.
  11. Hsiao L-T, Lin J-T, Yu I-T, et al: High serum hepatocyte growth factor level in patients with non-Hodgkin’s lymphoma. Eur J Haematol 2003;70:282–289.
  12. Sheen-Chen SM, Liu Y-W, Eng H-L, Chou F-F: Serum levels of hepatocyte growth factor in patients with breast cancer. Cancer Epidemiol Biomarkers Prev 2005;14:715–717.
  13. Beviglia L, Matsumoto K, Lin CS, Ziober BL, Kramer RH: Expression of the c-met/HGF receptor in human breast carcinoma: correlation with tumor progression. Int J Cancer 1997;74:301–309.
  14. Lengyel E, Prechtel D, Resau JH, et al: c-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer 2005;113:678–682.
  15. Taniguchi T, Toi M, Inada K, et al: Serum concentrations of hepatocyte growth factor in breast cancer patients. Clin Cancer Res 1995;1:1031–1034.
  16. Toi M, Taniguchi T, Ueno T, et al: Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer. Clin Cancer Res 1998;4:659–664.
  17. Parr C, Watkins G, Mansel RE, Jiang WG: Hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res 2004;10:202–211.
  18. Martin TA, Watkins G, Masel RE, Jiang WG: Hepatocyte growth factor disrupts tight junctions in human breast cancer cells. Cell Biol Int 2004;28:361–371.
  19. Hiscox S, Jiang WG: Association of the HGF/SF receptor, c-met, with the cell surface adhesion molecule, E-cadherin, and catenins in human tumor cells. Biochem Biophys Res Commun 1999;261:406–411.
  20. Mine S, Fuyisaki T, Kawahara C, et al: Hepatocyte growth factor enhances adhesion of breast cancer cells to endothelial cells in vitro through up-regulation of CD44. Exp Cell Res 2003;288:189–197.
  21. Zinser JW, Hortobagyi GN, Buzdar AU, Smith TL, Fraschini G: Clinical course of breast cancer patients with liver metastases. J Clin Oncol 1987;5:773–782.
  22. Pritchard KI: Liver metastases: can our understanding of their biology and prognostic value contribute to a strategy for optimum therapeutic management? Eur J Cancer 1997;33(suppl 7):S11–14.

    External Resources

  23. Wyld L, Gutteridge E, Pinder SE, et al: Prognostic factors for patients with hepatic metastases from breast cancer. Br J Cancer 2003;89:284–290.
  24. Hortobagyi GN: Can we cure limited metastatic breast cancer? J Clin Oncol 2002;20:707–718.
  25. Coskun U, Bukan N, Sancak B, et al: Serum hepatocyte growth factor and interleukin-6 levels can distinguish patients with primary or metastatic liver tumors from those with benign liver lesions. Neoplasma 2004;51:209–213.
  26. Taniguchi T, Toi M, Tominaga T: Increase in the circulating level of hepatocyte growth factor in breast cancer patients with distant metastases. Oncol Rep 1994;1:1199–1201.

    External Resources

  27. Maemura M, Iion T, Yokoe T, et al: Serum concentrations of hepatocyte growth factor in patients with metastatic breast cancer. Cancer Lett 1998;126:215–220.
  28. Nagy J, Curry GW, Hillan KJ, et al: Hepatocyte growth factor/scatter factor expression and c-met in primary breast cancer. Surg Oncol 1996;5:15–21.
  29. Edakuni G, Sasatomi E, Satoh T, Tokunaga O, Miyazaki K: Expression of the hepatocyte growth factor/c-Met pathway is increased at the cancer front in breast carcinoma. Pathol Int 2001;51:172–178.
  30. Birchmeier C, Gherardi E: Developmental roles of HGF/SF and its receptor, the c-met tyrosine kinase. Trends Cell Biol 1998;8:404–411.
  31. Elliott BE, Hung WL, Boag AH, Tuck AB: The role of hepatocyte growth factor (scatter factor) in epithelial-mesenchymal transition and breast cancer. Can J Physiol Pharmacol 2002;80:91–102.
  32. Tuck AB, Park M, Sterns EE, Boag A, Elliott BE: Coexpression of hepatocte growth factor and receptor (Met) in human breast carcinoma. Am J Pathol 1996;148:225–232.
  33. Brinkmann V, Foroutan H, Sachs M, Weidner KM, Birchmeier W: Hepatocyte growth factor/scatter factor induces a variety of tissue-specific morphogenic programs in epithelial cells. J Cell Biol 1995;131:1573–1586.
  34. Ma PC, Maulik G, Christensen J, Salgia R: c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 2003;22:309–325.
  35. Jiang WG, Hiscox S, Matsumoto K, Nakamura T: Hepatocyte growth factor/scatter factor. The molecular, cellular and clinical implications in cancer. Crit Rev Oncol Hematol 1999;29:209–248.
  36. Matsumoto K, Nakamura T: NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci 2003;94:321–327.
  37. Wen J, Matsumoto K, Taniura N, Tomioka D, Nakamura T: Hepatic gene expression of NK4, an HGF-antagonist/angiogenesis inhibitor, suppresses liver metastasis and invasive growth of colon cancer in mice. Cancer Gene Ther 2004;11:419–430.
  38. Hiscox S, Parr C, Nakamura T, Matsumoto K, Mansell RE, Jiang WG: Inhibition of HGF-induced breast cancer cell motility and invasion by the HGF variant, NK4. Breast Cancer Res Treat 2000;59:245–254.
  39. Martin T, Parr C, Davies G, et al: Growth and angiogenesis of human breast cancer in a nude mouse model is reduced by NK4, a HGF/SF antagonist. Carcinogenesis 2003;24:1317–1323.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50